ONI Names Sharon Krumm, PhD, RN, Editor of Oncology Nursing

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 10
Volume 10
Issue 10

MELVILLE, New York-The publishers of ONI are pleased to announce that Sharon K. Krumm, PhD, RN, will serve as Editor of Oncology Nursing. Dr. Krumm earned her bachelor of science in nursing from the University of Missouri School of Nursing, Columbia, and her MS and PhD from the University of Missouri.

MELVILLE, New York—The publishers of ONI are pleased to announce that Sharon K. Krumm, PhD, RN, will serve as Editor of Oncology Nursing. Dr. Krumm earned her bachelor of science in nursing from the University of Missouri School of Nursing, Columbia, and her MS and PhD from the University of Missouri.

Since 1996, she has been administrator and director of nursing at The Johns Hopkins Oncology Center, Baltimore. She is also assistant professor at The Johns Hopkins University Schools of Medicine and Nursing. Previously, she was director of nursing at the University of Missouri, Ellis Fischel Cancer Center. She joined Johns Hopkins in 1988 as director of nursing.

Dr. Krumm serves on the Board of Trustees of the American Cancer Society Mid-Atlantic Division. She has extensive research experience and is currently principal investigator for a study evaluating Johns Hopkins’ inpatient/outpatient care continuum program. She is the author, coauthor, or editor of 30 journal articles or abstracts and seven books.

Dr. Krumm brings to ONI a wealth of knowledge in the oncology nursing field and will be actively involved in selecting material specifically of interest to oncology nurses.

Related Videos
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Overall survival data with blinatumomab in the phase 3 E1910 study may be an “important development” in CD19-positive B-ALL.
Intraoperative radiation therapy may allow surgical and radiation oncologists to collaboratively visualize at-risk areas in patients with cancer.
Positive margin rates have not appeared to improve for patients with cancer undergoing surgical care based on several prior studies.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Related Content